Goldman Sachs Maintains Buy Rating on Health Net

Goldman Sachs maintains its Buy rating and 2011-12 EPS estimates on Health Net HNT after HNT announced its first-time 2011 revenue and earnings guidance. HNT expects EPS to be "at least $2.75" vs. Goldman Sachs' estimate of $2.90 and Street consensus of $2.80. Revenue is expected to be $12.0-$12.5 bn vs. GS' estimate of $11.7 bn, and the Street's consensus of $13.7 bn. Goldman Sachs maintains its $32 price target. HNT is trading at $26.88.